Page last updated: 2024-12-06

dt 5061

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination: contains norethindrone & ethinyl estradiol [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62925
SCHEMBL ID3835489
MeSH IDM0074111

Synonyms (101)

Synonym
ethinylestradiol and norethisterone
norethindrone and ethinyl estradiol
femcon fe
primidos
ovysmen
ortho-novum 1/35
zoran
sh b 259 ab
binovum
ortho-novum 10/11-28
ortho-novum 7/7/7
neocon
ovcon 50
ovcon 35
norimin
norminest
dt-5062(1/35)
dt 5061
duagynon
gynovlar
eve 20
e-con
oestro-primolut
sh 7.1122
trinovum
dt-5061
ovyrmen
lodose
netasyn
norimen
ortho-novum 777
ortho novum 7-7-7
brevion
dt 5062
ortho-novum 10/11
norinyl 1-35
ovcon-50
n.e.e. 1/35 28
ortho-novum 7/14-28
norcept-e 1/35 21
ortho-novum 1/35-21
norcept-e 1/35 28
ortho-novum 7/14-21
brevicon 21-day
tri-norinyl 21-day
ortho-novum 10/11-21
norethindrone and ethinyl estradiol (10/11)
ortho-novum 7/7/7-28
modicon 28
ovcon-35
norinyl 1+35 21-day
gencept 10/11-21
brevicon 28-day
norethin 1/35e-21
gencept 10/11-28
tri-norinyl 28-day
norethindrone and ethinyl estradiol (7/14)
norinyl 1+35 28-day
ortho-novum 1/35-28
modicon 21
n.e.e. 1/35 21
ortho-novum 7/7/7-21
norethin 1/35e-28
norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination
37270-71-6
norethindrone / ethinyl estradiol
leena
N049500000
alyacen 7/7/7
alyacen 1/35
ethynyl estradiol / norethindrone
ethinylestradiol-norethisterone mixt.
necon 7/7/7 28-day tablets
nortrel 7/7/7
norinyl 1 35
lo minastrin fe
norethisterone-ethynylestradiol mixt.
cyclafem 1/35
ethynylestradiol / norethindrone
norethindrone ethinyl estradiol
nylia 7/7/7
nortrel 1/35-28
nortrel 0.5/35-21
norethindron-ethinylestradiol mixt.
nortrel 0.5/35-28
balziva
nortrel 1/35-21
cyonanz
norethisterone-ethinylestradiol mixt.
kaitlib fe
zenchent
norethindrone-ethinylestradiol mixt.
nylia 1/35
balziva-28
aranelle
cyclafem 7/7/7
balziva-21
SCHEMBL3835489
(8r,9s,10r,13s,14s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol
17-hydroxy-19-norpregn-4-en-20-yn-3-one--19-norpregna-1(10),2,4-trien-20-yne-3,17-diol (1/1)
DTXSID00958416

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"No serious adverse effects were observed in either group."( A triphasic oral contraceptive pill, CTR-05: clinical efficacy and safety.
Ledger, WJ; Saxena, BB; Singh, M; Singh, R; Thomas, D, 1996
)
0.29
" The adverse events reported in both treatment groups are consistent with those expected with the use of combined hormonal contraceptives."( Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lu
Cromie, MA; Garceau, RJ; Kaunitz, AM, 1999
)
0.3

Pharmacokinetics

ExcerptReferenceRelevance
"Plasma concentration profiles and pharmacokinetic parameters have been obtained following single dose administration of three commonly used oral contraceptive steroid preparations, Ovral, Nordette and Norminest to Egyptian women."( Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
Back, DJ; el-Raghy, I; Fathalla, M; Makeram, M; Orme, ML; Osman, F; Salem, H, 1986
)
0.27
" Pharmacokinetic parameters, including AUC(0-24), C(max), and C(min), were calculated using noncompartmental methods, and drug interactions were evaluated using an ANOVA model by treatment group."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
" Twenty-one subjects completed the study and were included in the pharmacokinetic analysis; 4 discontinued for reasons unrelated to study drug and 2 discontinued because of adverse events."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
"Rilpivirine coadministration had no effect on (least square mean ratio, 90% confidence interval) ethinylestradiol Cmin (1."( Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Buelens, A; Crauwels, HM; Hoetelmans, RM; Stevens, M; van Heeswijk, RP, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" With the same contraceptive reliability its cycle stability is very much better than the monophase preparations, which are 40% high dosed in the progestin proportion (levonorgestrel and desogestrel)."( [Progress in oral contraception. Advantages of a levonorgestrel-containing 3-stage preparation over low-dose levonorgestrel and desogestrel containing monophasic combination preparations].
Lachnit-Fixson, U, 1984
)
0.27
" Blood samples were collected up to 24 hours after dosing on prespecified days."( Effect of vicriviroc with or without ritonavir on oral contraceptive pharmacokinetics: a randomized, open-label, parallel-group, fixed-sequence crossover trial in healthy women.
Kasserra, C; Li, J; March, B; O'Mara, E, 2011
)
0.37
"Co-administration of rilpivirine, at the therapeutic dosing regimen, with ethinylestradiol/norethindrone does not affect hormone pharmacokinetics, and is, therefore, unlikely to affect the efficacy or safety of this oral hormonal contraceptive."( Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers.
Buelens, A; Crauwels, HM; Hoetelmans, RM; Stevens, M; van Heeswijk, RP, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (102)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (50.00)18.7374
1990's28 (27.45)18.2507
2000's10 (9.80)29.6817
2010's11 (10.78)24.3611
2020's2 (1.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.37 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials41 (37.61%)5.53%
Reviews4 (3.67%)6.00%
Case Studies12 (11.01%)4.05%
Observational0 (0.00%)0.25%
Other52 (47.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]